Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated May 28, 2026, reports the announcement of positive pivotal Phase III clinical trial data for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B (CHB). The data from the B-Well 1 and B-Well 2 trials were published in the New England Journal of Medicine and presented at the European Association for the Study of the Liver (EASL) congress.
Key Financial and Operational Metrics
The filing focuses on clinical efficacy and regulatory status rather than financial performance. No revenue, profit, cash flow, margin, debt, or liquidity figures are provided in this document.
- Functional Cure Rate (Primary Endpoint): 19% in the overall study population (patients with baseline HBsAg ≤3000 IU/mL) versus 0% in the placebo group.
- Functional Cure Rate (Secondary Endpoint): 26% in patients with lower viral activity (baseline HBsAg ≤1000 IU/mL) versus 0% in the placebo group.
- Surface Antigen Reduction: 49% of recipients achieved a surface antigen level of ≤100 IU/mL one year after treatment ended (exploratory analysis).
- Study Population: 1,220 patients in the bepirovirsen arm and 614 in the placebo arm across 29 countries.
- Safety Profile: Acceptable tolerability; most frequent adverse events were injection site erythema, local pain, and temporary liver enzyme elevation.
Material Changes and Clinical Significance
The results represent a significant departure from the current standard of care, which typically requires lifelong therapy and achieves functional cure rates of less than 1%. Bepirovirsen demonstrated a statistically significant (p<0.001) improvement in functional cure rates. Additionally, the loss of surface antigen is associated with an 89% reduction in liver cancer risk and a 62% reduction in all-cause mortality.
Guidance, Outlook, and Strategic Developments
Regulatory Outlook: GSK anticipates the first regulatory decisions in Q3 2026. Bepirovirsen is under priority review by the US FDA (with Breakthrough and Fast Track Designations), the European Medicines Agency, Japan (SENKU designation), and China (Breakthrough Therapy and Priority Review).
Commercial Strategy: In May 2026, GSK entered a strategic collaboration with SinoBiopharmaceutical to accelerate patient access in China at launch.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in GSK's 2025 Annual Report on Form 20-F and Q1 2025 results.
Key Facts for Investor Verification
- Confirm the timeline for regulatory approval decisions expected in Q3 2026 across the US, Europe, Japan, and China.
- Verify the commercial terms and revenue-sharing structure of the new collaboration with SinoBiopharmaceutical for the Chinese market.
- Monitor the safety data post-approval, specifically regarding the reported temporary rise in liver enzymes.
- Assess the potential market size impact given the 240 million global CHB patients and the shift from lifelong therapy to a finite 6-month treatment course.
- Review the full risk factors in the 2025 Form 20-F to understand potential regulatory or commercialization hurdles not detailed in this press release.